11.7 C
London
Thursday, September 21, 2023

Emerging Growth Conference 62 September 6 & 7. Register now

Tag: ASX 1AD Biotech Medical Stocks

AD-214 RETURNS TO CLINICAL STUDIES

Key points: First dosing of AD-214 achieved in Phase I extension study On track to obtain interim results in 2023, full results in...

Unlocking Chronic Diseases with Next-Gen i-body Platform Technology from AdAlta (1AD)

Unlocking Chronic Diseases with Next-Gen i-body Platform Technology from AdAlta (1AD) 1AD stock carries a dramatically undervalued profile against its blue-sky upside target Emerging Growth Report...

$1.87 million raised in oversubscribed Shortfall facility

MELBOURNE Australia, 13 July 2023: AdAlta Limited (ASX:1AD), the clinical stage drug discovery company developing novel therapeutic products from its i-body platform is pleased...

New AD-214 Data Links Phase I Results With Efficacy; De-Risks Clinical...

Key points: • New data favourably links AD-214 preclinical animal studies and Phase I human clinical trial results to provide important dose frequency insights • AD-214 is designed to...

AdAlta (ASX: 1AD) IMPORTANT PHASE I EXTENSION CLINICAL STUDY OF AD-214...

29 June 2023 ASX Announcement IMPORTANT PHASE I EXTENSION CLINICAL STUDY OF AD-214 APPROVED Key highlights: Human Research Ethics Committee (HREC) has approved Phase I extension...